Immunological risk factors for infection after immunosuppressive and biologic therapies.
about
Clinical outcomes of immunoglobulin use in solid organ transplant recipients: protocol for a systematic review and meta-analysisInfluenza and Pneumococcal Vaccination in Hematological Malignancies: a Systematic Review of Efficacy, Effectiveness, and SafetyInfection risk in patients on multiple sclerosis therapeutics.Polymeric synthetic nanoparticles for the induction of antigen-specific immunological toleranceRheumatoid arthritis vs osteoarthritis in patients receiving total knee arthroplasty: perioperative outcomes.Multiple sclerosis treatment and infectious issues: update 2013.CBirTox is a selective antigen-specific agonist of the Treg-IgA-microbiota homeostatic pathway.Encapsulating an Immunosuppressant Enhances Tolerance Induction by Siglec-Engaging Tolerogenic Liposomes.[Infection risks in multiple sclerosis therapy by infusion of disease modifying drugs].Intravenous immunoglobulin as an intervention strategy of risk factor modification for prevention of severe infection in heart transplantation.Evaluation of an immunological score to assess the risk of severe infection in heart recipients.Multipeptide-coupled nanoparticles induce tolerance in 'humanised' HLA-transgenic mice and inhibit diabetogenic CD8+ T cell responses in type 1 diabetes.Alterations of naïve and memory B-cell subsets are associated with risk of rejection and infection in heart recipients.Decreased levels of serum complement C3 and natural killer cells add to the predictive value of total immunoglobulin G for severe infection in heart transplant recipients
P2860
Q27024904-F73678BA-53C6-4381-BCE0-3EE911069A8EQ28079486-CD6AA0DE-83B8-4F7C-A5C0-E6DE792FFC64Q30908652-E26BC93C-3692-44F7-AC51-BDE6D61E1C16Q34985424-661EE805-32AB-4FB8-958C-4B296DDF23A9Q37201007-2BB23489-165C-4F91-A80E-B0810A6EDD71Q38153471-FB1F3638-CBD8-4096-B440-933F9F79C3CCQ38657465-B5562240-01C6-45F5-B5DD-4623621240A4Q38754057-E6576E84-B8B9-4F7A-BFB3-E5F896CD33B4Q41102105-26D7940F-4495-48CE-9E0A-FED82B437EAAQ41577767-D6483D67-8552-4403-84EF-6C1FC62EF21BQ41758384-8B95516D-F1A8-4A96-AD70-3DCA89A2FE4FQ48666099-3D8B0BF1-AAE3-4B9C-8170-075010FCAC2DQ50897404-E0664039-D027-48D9-9BFB-789EAC1E5BEDQ57568967-5B968D3E-8DDF-40DE-A7FE-646FBA0841C2
P2860
Immunological risk factors for infection after immunosuppressive and biologic therapies.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Immunological risk factors for infection after immunosuppressive and biologic therapies.
@en
Immunological risk factors for infection after immunosuppressive and biologic therapies.
@nl
type
label
Immunological risk factors for infection after immunosuppressive and biologic therapies.
@en
Immunological risk factors for infection after immunosuppressive and biologic therapies.
@nl
prefLabel
Immunological risk factors for infection after immunosuppressive and biologic therapies.
@en
Immunological risk factors for infection after immunosuppressive and biologic therapies.
@nl
P2860
P356
P1476
Immunological risk factors for infection after immunosuppressive and biologic therapies
@en
P2093
Antonio Gallego
Nadia del Pozo
P2860
P304
P356
10.1586/ERI.10.178
P577
2011-04-01T00:00:00Z